- Home
- NRIM vs KALV Comparison
NRIM vs KALV Comparison
Compare NRIM & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRIM | KALV |
|---|---|---|
| Founded | 1990 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.4M | 551.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NRIM | KALV |
|---|---|---|
| Price | $26.98 | $16.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $27.83 |
| AVG Volume (30 Days) | 176.9K | ★ 956.5K |
| Earning Date | 01-23-2026 | 11-10-2025 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ 91.08 | N/A |
| EPS | ★ 2.80 | N/A |
| Revenue | ★ $201,544,000.00 | $1,426,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.55 | $204.16 |
| P/E Ratio | $9.64 | ★ N/A |
| Revenue Growth | ★ 42.34 | N/A |
| 52 Week Low | $16.18 | $7.30 |
| 52 Week High | $28.21 | $17.30 |
Technical Indicators
Market Signals| Indicator | NRIM | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 60.08 |
| Support Level | $26.68 | $15.12 |
| Resistance Level | $27.71 | $16.45 |
| Average True Range (ATR) | 0.62 | 0.88 |
| MACD | -0.09 | -0.06 |
| Stochastic Oscillator | 34.30 | 82.78 |
Price Performance
Historical ComparisonAbout NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.